Compare Hewlett Packard Enterprise Co (HPE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Neurocrine Biosciences Inc — how do they compare? Hewlett Packard Enterprise Co trades at $55.6 (market cap $72.01B), while Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B). The key difference: Hewlett Packard Enterprise Co is far larger — about 4.4× Neurocrine Biosciences Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HPE | NBIX | |
|---|---|---|
Market Cap | $72.01B | $16.46B |
Sector | Technology | Health |
52-Week High | $56.14 | $185.50 |
52-Week Low | $20.01 | $123.10 |
Enterprise Value | $87.96B | $16.48B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE stock trades at $54.67, up 2.72% recently, with a bullish technical signal from moving averages but overbought RSI readings. The company has beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.925. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows. Analysts maintain a consensus buy rating with a $69.81 price target, citing AI infrastructure demand.
The outlook is positive given AI-driven upgrades and institutional buying, but risks include volatile cash flows, elevated debt, and margin pressure. Investors should weigh strong analyst sentiment against execution risks in a competitive market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
